Abstract
CCN3, a tumour suppressor gene, is down-regulated as a result of BCR-ABL tyrosine kinase activity in Chronic Myeloid Leukaemia (CML). We have established a stable CCN3 expression model in the human K562 CML cell line and have further validated the role for CCN3 in the leukaemogenic process. K562 cells stably transfected with CCN3 (K562/CCN3; 2.25 × 106 copies per 50 ng cDNA) demonstrated over 50% reduction in cell growth in comparison to cells stably transfected with empty vector (K562/control; p = 0.005). K562/CCN3 cells had reduced colony formation capacity (reduced by 29.7%, p = 0.03) and reduced mitogenic signalling in comparison to K562/control cells (reduced by 29.5% (p = 0.002) and 37.4% (p = 0.017) for phosphorylation levels of ERK and AKT respectively). K562/CCN3 cells showed an accumulation of events within the subG0 phase of the cell cycle and increased apoptosis was confirmed by a three-fold increase in annexin V binding (p < 0.05). K562/CCN3 cells exposed to Imatinib (1 μM and 5 μM) showed an increase in events within the subG0 phase of cell cycle over 96 h and mirrored the enhanced cell kill demonstrated by Annexin staining. Wild type K562 cells treated with recombinant human Ccn3 (10 nM) in combination with Imatinib (5 μM) also displayed enhanced cell kill (p = 0.008). K562/CCN3 cells displayed increased adhesion to matrigel™ (2.92 ± 0.52 fold increase compared to K562/control) which was commensurate with increased expression of the alpha 6 and beta 4 integrins (6.53 ± 0.47 and 1.94 ± 0.07 fold increase in gene expression respectively (n = 3, p < 0.05)). CCN3 restores cellular growth regulatory properties that are absent in CML and sensitises CML cells to imatinib induced apoptosis. CCN3 may provide novel avenues for the development of alternate therapeutic strategies.
Similar content being viewed by others
References
Bhatia R, Munthe HA, Verfaillie CM (1999) Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors. Exp Hematol 27(9):1384–1396
Borland G, Cushley W (2004) Positioning the immune system: unexpected roles for alpha6-integrins. Immunology 111(4):381–383
Chevalier G, Yeger H, Martinerie C, Laurent M, Alami J, Schofield PN, Perbal B (1998) novH: differential expression in developing kidney and Wilm’s tumors. Am J Pathol 152(6):1563–1575
Deininger MW, Holyoake TL (2005) Can we afford to let sleeping dogs lie? Blood 105(5):1840–1841
Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96(10):3343–3356
De Pereda JM, Lillo MP, Sonnenberg A (2009) Structural basis of the interaction between integrin alpha6beta4 and plectin at the hemidesmosomes. EMBO J 28(8):1180–1190
Fu CT, Bechberger JF, Ozog MA, Perbal B, Naus CC (2004) CCN3 (NOV) interacts with connexin43 in C6 glioma cells: possible mechanism of connexin-mediated growth suppression. J Biol Chem 279(35):36943–36950
Fukunaga-Kalabis M, Martinez G, Liu ZJ, Kalabis J, Mrass P, Weninger W, Firth SM, Planque N, Perbal B, Herlyn M (2006) CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. J Cell Biol 175(4):563–569
Fukunaga-Kalabis M, Martinez G, Telson SM, Liu ZJ, Balint K, Juhasz I, Elder DE, Perbal B, Herlyn M (2008) Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene 27(18):2552–2560
Ginzinger DG (2002) Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol 30(6):503–512
Heaney NB, Holyoake TL (2007) Therapeutic targets in chronic myeloid leukaemia. Hematol Oncol 25(2):66–75
Holbourn KP, Acharya KR, Perbal B (2008) The CCN family of proteins: structure-function relationships. Trends Biochem Sci 33(10):461–473
Jorgensen HG, Holyoake TL (2001) A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia. Hematol Oncol 19(3):89–106
Lu W, McCallum L, Irvine AE (2009) A rapid and sensitive method for measuring cell adhesion. J Cell Comm Signal 3(2):147–149
Maillard M, Cadot B, Ball RY, Sethia K, Edwards DR, Perbal B, Tatoud R (2001) Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues. Mol Pathol: MP 54(4):275–280
Martinerie C, Gicquel C, Louvel A, Laurent M, Schofield PN, Le Bouc Y (2001) Altered expression of novH is associated with human adrenocortical tumorigenesis. J Clin Endocrinol Metab 86(8):3929–3940
McCallum L, Irvine AE (2009) CCN3–a key regulator of the hematopoietic compartment. Blood Rev 23(2):79–85
McCallum L, Price S, Planque N, Perbal B, Pierce A, Whetton AD, Irvine AE (2006) A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation. Blood 108(5):1716–1723
McCallum L, Lu W, Price S, Lazar N, Perbal B, Irvine AE (2009) CCN3: a key growth regulator in Chronic Myeloid Leukaemia. J Cell Comm Signal 3(2):115–124
Perbal B, Zuntini M, Zambelli D, Serra M, Sciandra M, Cantiani L, Lucarelli E, Picci P, Scotlandi K (2008) Prognostic value of CCN3 in osteosarcoma. Clin Canc Res 14(3):701–709
Perbal B, Lazar N, Zambelli D, Lopez-Guerrero JA, Llombart-Bosch A, Scotlandi K, Picci P (2009) Prognostic relevance of CCN3 in Ewing sarcoma. Hum Pathol 40(10):1479–1486
Sattler M, Salgia R (1998) Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells. Leukemia 12(5):637–644
Sin WC, Bechberger JF, Rushlow WJ, Naus CC (2008) Dose-dependent differential upregulation of CCN1/Cyr61 and CCN3/NOV by the gap junction protein Connexin43 in glioma cells. J Cell Biochem 103(6):1772–1782
Streuli CH, Akhtar n (2009) Signal co-operation between integrins and other receptor systems. Biochem J 418(3):491–506
Verfaillie CM (1998) Adhesion receptors as regulators of the hematopoietic process. Blood 92(8):2609–2612
Verfaillie CM, Hurley R, Zhao RC, Prosper F, Delforge M, Bhatia R (1997) Pathophysiology of CML: do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone? J Lab Clin Med 129(6):584–591
Wong S, Witte ON (2001) Modelling Philadelphia chromosome positive leukemias. Oncogene 20(40):5644–5659
Acknowledgements
This work has been supported by funding from the Northern Ireland Leukaemia Research Fund (NILRF) and Elimination of Leukaemia Fund (ELF, UK).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McCallum, L., Lu, W., Price, S. et al. CCN3 suppresses mitogenic signalling and reinstates growth control mechanisms in Chronic Myeloid Leukaemia. J. Cell Commun. Signal. 6, 27–35 (2012). https://doi.org/10.1007/s12079-011-0142-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12079-011-0142-2